Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 772 across all filing types
Latest filing 2025-05-15 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about an upcoming earnings conference call for the quarter and year ended 31st March 2025. It includes details such as the date and time of the call, participants, and dial-in information. The document does not contain any financial results or detailed financial data itself, but rather serves as an announcement of the earnings call event. According to the classification rules, announcements of conference calls are classified as Call Transcript (CT) only if they contain the full transcript. Since this is only an intimation of the call, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other categories. The document length is short (2454 characters), and it is clearly an announcement, not the report or transcript itself.
2025-05-15 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming earnings conference call for the quarter and year ended 31st March 2025. It references the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, indicating a regulatory compliance announcement. The content includes details about the date, time, and participants of the earnings call, along with dial-in information and contact details for further inquiries. The document does not contain actual financial results or detailed financial statements but serves to inform stakeholders about the scheduled earnings call event. Given the nature of the document as an announcement of a conference call rather than the call transcript itself or the earnings release, the appropriate classification is Call Transcript (CT) since it is directly related to the earnings call event, but since it is only an intimation and not the transcript, the best fit is Call Transcript (CT) as per the definitions provided, which includes full text transcripts of company conference calls. However, since this document is only an intimation and not the transcript, it is more appropriate to classify it as Regulatory Filings (RNS) because it is a regulatory announcement about the earnings call, not the transcript or the earnings release itself. The document length is short (2454 characters), and it is an announcement rather than the report or transcript itself. Therefore, the correct classification is Regulatory Filings (RNS).
2025-05-15 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-05-14 English
Board Meeting — Financial Results/Dividend
Board/Management Information Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board Meeting scheduled for May 22, 2025. The purpose of the meeting includes considering and approving the audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, and recommending a final dividend. The document also mentions the closure of the trading window for designated persons until 48 hours after the declaration of these results. The document does not contain the financial results themselves but is an announcement of the Board Meeting where these results will be approved and announced. It is a regulatory disclosure under SEBI regulations about the Board Meeting agenda, not the actual financial report or earnings release. Therefore, it fits best under Board/Management Information (MANG) as it relates to a Board Meeting notice and agenda.
2025-05-14 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March 2025. It is issued by the Registrar and Transfer Agent and addressed to stock exchanges. The document is short (1357 characters) and primarily serves as a certification of compliance rather than containing financial data or detailed report content. It does not present financial statements or management discussion. Therefore, it is best classified as a Regulatory Filing (RNS), which covers officer certifications and compliance confirmations.
2025-04-07 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the closure of the trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations. It informs about the trading window closure period around the announcement of audited financial results for the quarter and year ended March 31, 2025. The document does not contain any financial data, results, or detailed report but is an announcement related to trading restrictions prior to financial results disclosure. It is not an Annual Report, Earnings Release, or Interim Report itself, nor is it a certification or voting result. The document is a regulatory announcement about trading restrictions, which fits best under Regulatory Filings (RNS). The document length is short (1724 characters), and it is clearly an announcement, not the report itself.
2025-03-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.